Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 21, 2015, Pages 2241-2250

  Libman, Ingrid M ^a   Miller, Kellee M ^b   DiMeglio, Linda A ^c   Bethin, Kathleen E ^d   Katz, Michelle L ^e   Shah, Avni ^f   Simmons, Jill H ^g   Haller, Michael J ^h   Raman, Sripriya ⁱ   Tamborlane, William V ^j   Coffey, Julie K ^k   Saenz, Ashleigh M ^b   Beck, Roy W ^b   Nadeau, Kristen J ^l  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e JOSLIN DIABETES CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ CHILDREN S MERCY HOSPITAL   (United States)

^j YALE UNIVERSITY   (United States)

^k UNIVERSITY OF IOWA   (United States)

^l UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALYSIS; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; OBESITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84949522230     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.16174     Document Type: Article

References (19)

1. Libman IM, PietropaoloM, Arslanian SA, LaPorte RE, Becke r DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003;26(10):2871-2875.
2. DuBose SN, Hermann JM, TamborlaneWV, et al Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J Pediatr. 2015;167 (3):627-632e4-4.
3. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborl aneWV. Impaired insulin action in puberty: A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315(4):215-219.
4. Bjornstad P, Snell-Bergeon JK, Nad eau KJ, Maahs DM. Insulin sensitivity and complications in type 1 diabetes: New insights.World J Diabetes. 2015;6(1):8-16.
5. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petr ie JR. Insulin resistance in type 1 diabetes: What is 'double diabetes' and what are the risks? Diabetologia. 2013;56(7):1462-1470.
6. Nadeau KJ, Regensteiner JG, Bauer TA, et al. Ins ulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010;95(2):513-521.
7. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes. 2011;60(1):306-314.
8. Specht BJ,Wadwa RP, Snell-Bergeon JK, Nadeau KJ, Bishop FK, Maahs DM. Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes. J Pediatr. 2013; 162(2):297-301.
9. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect ofmetformin: Therapeutic and cellular mechanisms. Drugs. 1999; 58(suppl 1):31-39.
10. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: A systematic review of efficacy. Diabetologia. 2010;53(5):809-820.
11. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care. 2003;26(1):138-143.
12. Nadeau KJ, Chow K, Alam S, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: A randomized, double-blinded placebo-controlled study. Pediatr Diabe tes. 2015;16 (3):196-203.
13. Nwosu BU, Maranda L, Cullen K, et al. A randomized, double-blind, pla cebo-controlled trial of adjunctivemetformin therapy in overweight/obese youth with type 1 diabetes. PLoS One. 2015;10(9):e0137525.
14. Sä rnblad S, Kroon M, Aman J. Metformin as additiona l therapy in adolescents with poorly controlled type 1 diabetes: Randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323-329.
15. Centers for Diseas e Control and Prevention. CDC growth charts: United States. 2000. http://www.cdc.gov/growthcharts/charts.htm. Accessed October 5, 2015.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
17. Little RJA, Rubin DB. Statistical AnalysisWith Missing Data. Hoboken, NJ:Wiley; 1987.
18. Lund SS Tarnow L Astrup AS et al. Effect of adjunctmetformin treatment in patients with type-1 diabetes an d persistent inadequate glycaemic control:. a randomized study. PLoS One.2008. 3. 10. e3363.
19. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunctmetformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11(10):966-977.